Keyword: Ionis Pharmaceuticals
For $250 million up front, Akcea is licensing an antisense therapy to Pfizer, to be developed for “certain cardiovascular and metabolic diseases.”
A week after Sarah Boyce exited Akcea, she's at the helm of Avidity Biosciences, a company aiming to take antibody-drug conjugates to the next level.
Akcea CEO Paula Soteropoulos, President Sarah Boyce and Chief Operating Officer Jeff Goldberg are bidding the company adieu.
The deal comes shortly after GlaxoSmithKline achieved clinical proof of concept for the Ionis-partnered hepatitis B program.
ALS patients on the highest dose of Biogen's tofersen (BIIB067) showed a slowdown in the progression of symptoms in a phase 1 trial.
The decision sets Novartis up to test the RNA-targeting drug in a phase 3 cardiovascular outcomes trial.
Akcea and Ionis' self-administered Tegsedi is more convenient than Alnylam's Onpattro, but it comes with a boxed warning.
ProQR is licensing an RNA medicine from Ionis Pharmaceuticals for the treatment of retinitis pigmentosa, a form of rare, inherited blindness.
Stoke has completed a meaty $90 million second funding round as the startup eyes getting its leading candidate into the clinic by 2020.
An antisense technology for silencing genes that contribute to hampered insulin production may help treat Type 2 diabetes.